Next Article in Journal
Daily Dietary Selenium Intake in a High Selenium Area of Enshi, China
Next Article in Special Issue
The Role of Gut Microbiota on Insulin Resistance
Previous Article in Journal
Extracts, Anthocyanins and Procyanidins from Aronia melanocarpa as Radical Scavengers and Enzyme Inhibitors
Previous Article in Special Issue
Gut Microbiota as Potential Therapeutic Target for the Treatment of Cow’s Milk Allergy
Article Menu

Export Article

Open AccessReview
Nutrients 2013, 5(3), 679-699;

Role of Probiotics in Short Bowel Syndrome in Infants and Children—A Systematic Review

Department of Neonatology, King Edward Memorial Hospital for Women, Subiaco, Perth, WA 6008, Australia
Centre for Neonatal Research and Education, University of Western Australia, Perth, WA 6008, Australia
Department of Neonatology, Princess Margaret Hospital, Perth, WA 6008, Australia
Author to whom correspondence should be addressed.
Received: 19 December 2012 / Revised: 11 February 2013 / Accepted: 19 February 2013 / Published: 5 March 2013
(This article belongs to the Special Issue Gut Microbiota and Gut Function)
Full-Text   |   PDF [458 KB, uploaded 5 March 2013]   |  


Short bowel syndrome (SBS) is a cause of significant morbidity and mortality in children. Probiotics, due to their beneficial effects on the gastrointestinal tract (e.g., improving gut barrier function, motility, facilitation of intestinal adaptation and decreasing pathogen load and inflammation) may have a therapeutic role in the management of SBS. To conduct a systematic review of the current evidence for the effects of probiotic supplementation in children with SBS, the standard Cochrane methodology for systematic reviews was used. The databases, Pubmed, Embase, ACTR, CENTRAL, and the international trial registry, and reference lists of articles were searched for randomised (RCT) or quasi-randomised controlled trials reporting on the use of probiotics in SBS. Our search revealed no RCTs on the use of probiotics in children with SBS. We found one small cross-over RCT (placebo controlled crossover clinical trial), one case control study and nine case reports on the use of probiotics in children with SBS. In the crossover RCT, there was no consistent effect on intestinal permeability (primary outcome) after supplementation with Lactobacillus rhamnosus (LGG) in nine children with SBS. The case control study (four cases: four controls) reported a trend for increase in height and weight velocity and improvement in non-clinical outcomes, such as gut flora, lymphocyte count and serum prealbumin. Five of the nine case reports showed that children (n = 12) with SBS were benefited (e.g., cessation of diarrhoea, improved faecal flora, weight gain and weaning from parenteral nutrition) by probiotic supplementation. The remaining four reported on the adverse effects, such as Lactobacillus sepsis (n = 3) and d-lactic acidosis (n = 2). There is insufficient evidence on the effects of probiotics in children with SBS. The safety and efficacy of probiotic supplementation in this high-risk cohort needs to be evaluated in large definitive trials. View Full-Text
Keywords: infants; children; probiotics; review; short bowel syndrome infants; children; probiotics; review; short bowel syndrome

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Reddy, V.S.; Patole, S.K.; Rao, S. Role of Probiotics in Short Bowel Syndrome in Infants and Children—A Systematic Review. Nutrients 2013, 5, 679-699.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top